S&P 500   3,390.68 (-0.30%)
DOW   27,463.19 (-0.80%)
QQQ   282.66 (+0.78%)
AAPL   116.60 (+1.35%)
MSFT   213.25 (+1.51%)
FB   283.29 (+2.23%)
GOOGL   1,598.88 (+0.92%)
AMZN   3,286.33 (+2.47%)
TSLA   424.68 (+1.05%)
NVDA   535.87 (+1.94%)
BABA   317.14 (+3.35%)
CGC   18.66 (+0.70%)
GE   7.10 (-3.79%)
MU   51.96 (-0.35%)
AMD   78.88 (-4.07%)
T   26.92 (-1.68%)
F   7.92 (-1.37%)
ACB   4.00 (-9.09%)
GILD   60.01 (+0.08%)
NFLX   488.93 (+0.14%)
NIO   28.44 (+9.34%)
BA   155.24 (-3.48%)
DIS   123.31 (-0.60%)
S&P 500   3,390.68 (-0.30%)
DOW   27,463.19 (-0.80%)
QQQ   282.66 (+0.78%)
AAPL   116.60 (+1.35%)
MSFT   213.25 (+1.51%)
FB   283.29 (+2.23%)
GOOGL   1,598.88 (+0.92%)
AMZN   3,286.33 (+2.47%)
TSLA   424.68 (+1.05%)
NVDA   535.87 (+1.94%)
BABA   317.14 (+3.35%)
CGC   18.66 (+0.70%)
GE   7.10 (-3.79%)
MU   51.96 (-0.35%)
AMD   78.88 (-4.07%)
T   26.92 (-1.68%)
F   7.92 (-1.37%)
ACB   4.00 (-9.09%)
GILD   60.01 (+0.08%)
NFLX   488.93 (+0.14%)
NIO   28.44 (+9.34%)
BA   155.24 (-3.48%)
DIS   123.31 (-0.60%)
S&P 500   3,390.68 (-0.30%)
DOW   27,463.19 (-0.80%)
QQQ   282.66 (+0.78%)
AAPL   116.60 (+1.35%)
MSFT   213.25 (+1.51%)
FB   283.29 (+2.23%)
GOOGL   1,598.88 (+0.92%)
AMZN   3,286.33 (+2.47%)
TSLA   424.68 (+1.05%)
NVDA   535.87 (+1.94%)
BABA   317.14 (+3.35%)
CGC   18.66 (+0.70%)
GE   7.10 (-3.79%)
MU   51.96 (-0.35%)
AMD   78.88 (-4.07%)
T   26.92 (-1.68%)
F   7.92 (-1.37%)
ACB   4.00 (-9.09%)
GILD   60.01 (+0.08%)
NFLX   488.93 (+0.14%)
NIO   28.44 (+9.34%)
BA   155.24 (-3.48%)
DIS   123.31 (-0.60%)
S&P 500   3,390.68 (-0.30%)
DOW   27,463.19 (-0.80%)
QQQ   282.66 (+0.78%)
AAPL   116.60 (+1.35%)
MSFT   213.25 (+1.51%)
FB   283.29 (+2.23%)
GOOGL   1,598.88 (+0.92%)
AMZN   3,286.33 (+2.47%)
TSLA   424.68 (+1.05%)
NVDA   535.87 (+1.94%)
BABA   317.14 (+3.35%)
CGC   18.66 (+0.70%)
GE   7.10 (-3.79%)
MU   51.96 (-0.35%)
AMD   78.88 (-4.07%)
T   26.92 (-1.68%)
F   7.92 (-1.37%)
ACB   4.00 (-9.09%)
GILD   60.01 (+0.08%)
NFLX   488.93 (+0.14%)
NIO   28.44 (+9.34%)
BA   155.24 (-3.48%)
DIS   123.31 (-0.60%)
Log in
NASDAQ:RDUS

Radius Health Stock Forecast, Price & News

$13.80
-0.08 (-0.58 %)
(As of 10/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.58
Now: $13.80▼
$13.96
50-Day Range
$10.80
MA: $12.36▼
$13.86
52-Week Range
$10.15
Now: $13.80▼
$29.89
Volume242,114 shs
Average Volume594,474 shs
Market Capitalization$641.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More
Radius Health logo

Beat the Market (BTM) Rank™

Analyst Opinion: 4.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.10 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDUS
Previous Symbol
CUSIPN/A
CIK1428522
Webwww.radiuspharm.com
Phone617-551-4000
Employees398

Debt

Debt-to-Equity RatioN/A
Current Ratio2.43
Quick Ratio2.35

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$173.32 million
Price / Sales3.70
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.92) per share
Price / Book-15.00

Profitability

EPS (Most Recent Fiscal Year)($2.89)
Net Income$-132,990,000.00
Net Margins-67.99%
Return on EquityN/A
Return on Assets-66.22%

Miscellaneous

Outstanding Shares46,472,000
Market Cap$641.31 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$13.80
-0.08 (-0.58 %)
(As of 10/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Radius Health (NASDAQ:RDUS) Frequently Asked Questions

How has Radius Health's stock price been impacted by COVID-19 (Coronavirus)?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RDUS stock has decreased by 14.1% and is now trading at $13.80.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Radius Health?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Radius Health.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Radius Health.

How can I listen to Radius Health's earnings call?

Radius Health will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) released its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.82) by $0.13. The biopharmaceutical company had revenue of $50.11 million for the quarter, compared to analysts' expectations of $48.43 million.
View Radius Health's earnings history.

What price target have analysts set for RDUS?

8 brokerages have issued 1 year target prices for Radius Health's stock. Their forecasts range from $14.00 to $27.00. On average, they anticipate Radius Health's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 55.8% from the stock's current price.
View analysts' price targets for Radius Health.

Who are some of Radius Health's key competitors?

Some companies that are related to Radius Health include Axsome Therapeutics (AXSM), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), I-Mab (IMAB), Seres Therapeutics (MCRB), Aimmune Therapeutics (AIMT), Pacira BioSciences (PCRX), Xencor (XNCR), Karuna Therapeutics (KRTX), Corcept Therapeutics (CORT), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), Amarin (AMRN), Zymeworks (ZYME) and uniQure (QURE).
View all competitors.

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

Who are Radius Health's key executives?

Radius Health's management team includes the following people:
  • Mr. Jesper Høiland, Pres, CEO & Director (Age 59)
  • Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)
  • Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Brian Nicholas Harvey, Advisor (Age 58)
  • Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.38%) and Pacer Advisors Inc. (0.01%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, Target N V Biotech and Willard H Dere.
View institutional ownership trends for Radius Health.

Which major investors are buying Radius Health stock?

RDUS stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Pacer Advisors Inc.. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, and Target N V Biotech.
View insider buying and selling activity for Radius Health.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $13.80.

How big of a company is Radius Health?

Radius Health has a market capitalization of $641.31 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]

This page was last updated on 10/27/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.